The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Open accessAbstract
BACKGROUNDNirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (M pro ) inhibitor with potent pan-human-coronavirus activity in vitro. METHODSWe conducted a phase 2-3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days.Covid-19-related hospitalization or death from any cause through day 28, viral load, and safety were evaluated. RESULTSA total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group).In the planned interim analysis of patients treated within 3 days after symptom onset (modified intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19-related hospitalization or death by day 28 was lower in the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence interval [CI], -9.04 to -3.59; P<0.001; relative risk reduction, 89.1%); the incidence was 0.77% (3 of 389 patients) in the nirmatrelvir group, with 0 deaths, as compared with 7.01% (27 of 385 patients) in the placebo group, with 7 deaths.Efficacy was maintained in the final analysis involving the 1379 patients in the modified intention-to-treat population, with a difference of -5.81 percentage points (95% CI, -7.78 to -3.84; P<0.001; relative risk reduction, 88.9%).All 13 deaths occurred in the placebo group.The viral load was lower with nirmatrelvir plus ritonavir than with placebo at day 5 of treatment, with an adjusted mean difference of -0.868 log 10 copies per milliliter when treatment was initiated within 3 days after the onset of symptoms.The incidence of adverse events that emerged during the treatment period was similar in the two groups (any adverse event, 22.6% with nirmatrelvir plus ritonavir vs. 23.9% with placebo; serious adverse events, 1.6% vs. 6.6%; and adverse events leading to discontinuation of the drugs or placebo, 2.1% vs. 4.2%).Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo. CONCLUSIONSTreatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns.(Supported by Pfizer; ClinicalTrials.govnumber, NCT04960202.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Paxlovid was shown to be highly effective at preventing progression to severe COVID-19 in symptomatic patients105.”
From Advances in covalent drug discovery (2022) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.010 · Cited by 11,449
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis
Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., Li, Q., Jiang, C., Zhou, Y., Liu, S., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.021 · Cited by 2,074
An oral SARS-CoV-2 M pro inhibitor clinical candidate for the treatment of COVID-19
Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science · doi:10.1126/science.abl4784 · Cited by 2,033
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,002
Mesfin, Y. M., Blais, J. E., Kibret, K. T., Tegegne, T. K., Cowling, B. J., & Wu, P. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae163 · Cited by 21
Harris, V. C., Holmes, J., Gbinigie, O. A., Rahman, N. M., Richards, D. B., Hayward, G., Dorward, J., Lowe, D. M., Standing, J. F., Breuer, J., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00431-6 · Cited by 21
SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development
Angius, F., Puxeddu, S., Zaimi, S., Canton, S., Nematollahzadeh, S., Pibiri, A., Delogu, I., Alvisi, G., Moi, M. L., & Manzin, A. (2024) · Vaccines · doi:10.3390/vaccines13010017 · Cited by 22
Phan, T., Ribeiro, R. M., Edelstein, G. E., Boucau, J., Uddin, R., Marino, C., Liew, M. Y., Barry, M., Choudhary, M. C., Tien, D., et al. (2025) · Journal of Virology · doi:10.1128/jvi.01623-24 · Cited by 21
Abdelnabi, R., Maes, P., Jonghe, S. D., Weynand, B., & Neyts, J. H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1072202 · Cited by 21
Nirmatrelvir Resistance in SARS-CoV-2 Omicron_BA.1 and WA1 Replicons and Escape StrategiesPreprint
Lan, S., Neilsen, G., Slack, R. L., Cantara, W. A., Castaner, A. E., Lorson, Z. C., Lulkin, N., Zhang, H., Lee, J., Cilento, M. E., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.31.522389 · Cited by 22
SARS-CoV-2 Resistance to Small Molecule Inhibitors
Lopez, U. M., Hasan, M. M., Havranek, B., & Islam, S. M. (2024) · Current Clinical Microbiology Reports · doi:10.1007/s40588-024-00229-6 · Cited by 20
Kung, Y.-A., Chuang, C.-H., Chen, Y.-C., Yang, H.-P., Li, H.-C., Chen, C., Janapatla, R. P., Chen, C.-J., Shih, S., & Chiu, C. (2024) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2024.08.021 · Cited by 20
Hammond, J., Leister-Tebbe, H. K., Gardner, A., Abreu, P. C., Bao, W., Wisemandle, W., Ansari, W., Harrington, M. A., Campos, J. A. S., Chew, K. W., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae551 · Cited by 22
Self-citationXu, X., Zhou, S., Chen, C., Li, J., Wu, H., Jin, G., Zhou, J., Wang, G., Cao, M., Sun, D., et al. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154514 · Cited by 20
Monoclonal Antibody and Antiviral Therapy for Mild-to-Moderate COVID-19 in Pediatric Patients
Vora, S. B., Englund, J. A., Trehan, I., Waghmare, A., Kong, A., Adler, A., & Zerr, D. M. (2022) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003740 · Cited by 20
Martin‐Blondel, G., Marcelin, A., Soulié, C., Kaisaridi, S., Lusivika‐Nzinga, C., Zafilaza, K., Dorival, C., Nailler, L., Boston, A., Ronchetti, A., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.12.016 · Cited by 20
The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data
Petrakis, V., Rafailidis, P. I., Trypsianis, G. A., Papazoglou, D., & Panagopoulos, P. (2023) · Viruses · doi:10.3390/v15040976 · Cited by 20
Paxlovid for hospitalized COVID-19 patients with chronic kidney disease
Cai, H., Yan, J., Liu, S., Li, P., Li, D., Zhan, Y., Lu, J., Li, Z., Sun, Y., Zhu, M., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105659 · Cited by 20
Sjaarda, C. P., Lau, L. Y. S., Simpson, J. T., Fattouh, R., Biondi, M. J., Maguire, F., Campigotto, A. J., Feng, Y., Tozer, K., Wong, H., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.24963 · Cited by 20
Tian, H., Yang, C., Song, T., Zhou, K., Wen, L., Tian, Y., Tang, L., Xu, W., & Zhang, X. (2023) · Reviews in Medical Virology · doi:10.1002/rmv.2473 · Cited by 20
Wei, A., Zeng, L., Wang, L., Gui, L., Zhang, W., Gong, X., Li, J., & Liu, D. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274294 · Cited by 20
Lécuyer, D., Nardacci, R., Tannous, D., Gutierrez-Mateyron, E., Nathan, A. D., Subra, F., Primio, C. D., Quaranta, P., Petit, V., Richetta, C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1270081 · Cited by 21
Horga, A., Saenz, R., Yılmaz, G., Campos, J. A. S., Pietropaolo, K., Stubbings, W. J., Collinson, N., Ishak, L. M., Zrinscak, B., Belanger, B., et al. (2023) · Future Virology · doi:10.2217/fvl-2023-0115 · Cited by 20
Self-citationWong, C. K. H., Lau, J. J., Au, I. C. H., Lau, K. T. K., Hung, I. F., Peiris, M. J. S., Leung, G. M., & Wu, J. T. K. (2023) · Nature Communications · doi:10.1038/s41467-023-43706-0 · Cited by 20
Sasaki, M., Sugi, T., Iida, S., Hirata, Y., Kusakabe, S., Konishi, K., Itakura, Y., Tabata, K., Kishimoto, M., Kobayashi, H., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104950 · Cited by 20
Singh, S., Boyd, S., Schilling, W. H., Watson, J. A., Mukaka, M., & White, N. J. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae045 · Cited by 21
Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection
Qiao, Y., Wotring, J. W., Zhang, C. J., Jiang, X., Xiao, L., Watt, A., Gattis, D., Scandalis, E., Freier, S. M., Zheng, Y., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281281 · Cited by 21
Borgo, C. D., Garattini, S. K., Bortignon, C., Carraro, A., Trento, D. D., Gasperin, A., Grimaldi, A., Maria, S. G. D., Corazza, S., Tieghi, T., et al. (2023) · Viruses · doi:10.3390/v15041025 · Cited by 20
Parums, D. V. (2022) · Medical Science Monitor · doi:10.12659/msm.938532 · Cited by 20
COVID drug Paxlovid was hailed as a game-changer. What happened?
Kozlov, M. (2023) · Nature · doi:10.1038/d41586-022-04576-6 · Cited by 20
Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis
Ibrahim, S., Siemieniuk, R. A. C., Oliveros, M. J., Islam, N., Martinez, J. P. D., Izcovich, A., Qasim, A., Zhao, Y., Zaror, C., Yao, L., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081165 · Cited by 20
Sherman, A. C., Gray, G., Cao, B., To, K. K., Rouphael, N., Restrepo, A. M. H., Gordon, A. C., & Baden, L. R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00662-x · Cited by 19
Martin‐Blondel, G., Marcelin, A., Soulié, C., Kaisaridi, S., Lusivika‐Nzinga, C., Dorival, C., Nailler, L., Boston, A., Melenotte, C., Gaube, G., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.04.010 · Cited by 19
Larsen, C. S. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.06.059 · Cited by 19
Hashash, J. G., Desai, A., Kochhar, G. S., & Farraye, F. A. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.09.011 · Cited by 19
Sullivan, M. M., Perrine, C. G., Kelleher, J., Kanwar, O., Kuwabara, S. A., Bennett, K., Jackson, B. R., Patel, P., & Pennini, M. E. (2022) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7143a3 · Cited by 19
Bugatti, A., Filippini, F., Messali, S., Giovanetti, M., Ravelli, C., Zani, A., Ciccozzi, M., Caruso, A., & Caccuri, F. (2023) · Viruses · doi:10.3390/v15020332 · Cited by 20
A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19
Banerjee, S., Banerjee, D., Singh, A., Kumar, S., Pooja, D., Ram, V., Kulhari, H., & Saharan, V. A. (2023) · Vaccines · doi:10.3390/vaccines11020332 · Cited by 19
Ghoula, M., Naceri, S., Sitruk, S., Flatters, D., Moroy, G., & Camproux, A. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.03.029 · Cited by 20
SARS-CoV-2-Induced Myocarditis: A State-of-the-Art Review
Nappi, F., & Singh, S. (2023) · Viruses · doi:10.3390/v15040916 · Cited by 20
Wu, Y., Feng, X., Gong, M., Han, J., Jiao, Y., Li, S., Li, T., Shen, C., Wang, H., Yu, X., et al. (2023) · Health care science · doi:10.1002/hcs2.45 · Cited by 19
Jilg, N., Chew, K. W., Giganti, M. J., Daar, E. S., Wohl, D. A., Javan, A. C., Kantor, A., Moser, C., Coombs, R. W., Neytman, G., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad342 · Cited by 19
Liu, T., Wu, J., Huang, P., Tsai, Y., & Lai, C. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28951 · Cited by 19
Zhu, K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1228548 · Cited by 19
Piacentini, S., Riccio, A., Santopolo, S., Pauciullo, S., Frazia, S. L., Rossi, A., Rossignol, J., & Santoro, M. G. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1206951 · Cited by 22
Zheng, B., Tazare, J., Nab, L., Green, A. C. A., Curtis, H. J., Mahalingasivam, V., Herrett, E. L., Costello, R. E., Eggo, R. M., Speed, V., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100741 · Cited by 19
Mustali, J., Yasuda, I., Hirano, Y., Yasuoka, K., Gautieri, A., & Arai, N. (2023) · RSC Advances · doi:10.1039/d3ra06375e · Cited by 19
Tian, L., Qiang, T., Yang, X., Yue, G., Zhai, X., Kang, K., Du, C., Lu, Q., Gao, H., Zhang, D., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115979 · Cited by 19
Comparison of post-acute sequelae following hospitalization for COVID-19 and influenza
Liu, T., Huang, P., Wu, J., Chuang, M., Hsu, W., Tsai, Y., & Lai, C. (2023) · BMC Medicine · doi:10.1186/s12916-023-03200-2 · Cited by 19
Colchicine—The Divine Medicine against COVID-19
Mitev, V. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14070756 · Cited by 19
Han, J., Wzorek, A., Dhawan, G., Zhang, W., Sorochinsky, A. E., Ono, T., & Soloshonok, V. A. (2024) · Ukrainica Bioorganica Acta · doi:10.15407/bioorganica2024.01.003 · Cited by 19
Interactions between COVID-19 and Lung Cancer: Lessons Learned during the Pandemic
Bian, D. J. H., Sabri, S., & Abdulkarim, B. (2022) · Cancers · doi:10.3390/cancers14153598 · Cited by 21
Kwok, W. C., Tsoi, M. F., Leung, I. S. H., Tsui, C. K., Tam, T. C. C., Ho, J., Lam, D. C. L., Ip, M., & Ho, P. (2023) · Viruses · doi:10.3390/v15030610 · Cited by 20
Huang, P., Liu, T., Wu, J., Tsai, Y., & Lai, C. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28621 · Cited by 19
Mutoh, Y., Umemura, T., Nishikawa, T., Kondo, K., Nishina, Y., Soejima, K., Noguchi, Y., Bando, T., Ota, S., Shimahara, T., et al. (2023) · Viruses · doi:10.3390/v15030811 · Cited by 19
Qasmieh, S. A., Robertson, M. M., Teasdale, C. A., Kulkarni, S., Jones, H. E., Larsen, D. A., Dennehy, J. J., McNairy, M. L., Borrell, L. N., & Nash, D. (2023) · Communications Medicine · doi:10.1038/s43856-023-00321-w · Cited by 19
Mohammed, A. O., Abo-idris, M., Makki, A. A., Ibraheem, W., & Alzain, A. A. (2022) · Structural Chemistry · doi:10.1007/s11224-022-01999-9 · Cited by 18
Blasiak, A., Truong, A. T. L., Wang, P., Hooi, L., Chye, D. H., Tan, S., You, K., Remus, A., Allen, D. M., Chai, L. Y. A., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c06366 · Cited by 17
Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir
Wong, G. L., Hui, V. W., Yip, T. C., Lui, G. C.-Y., Hui, D. S. C., & Wong, V. W. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.09.008 · Cited by 18
Huang, C., Lu, T.-L., & Lin, L. (2023) · Antibiotics · doi:10.3390/antibiotics12020393 · Cited by 18
Yan, D., & Yan, B. (2023) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12889 · Cited by 18
Ambrosio, F. A., Costa, G., Romeo, I., Esposito, F., Alkhatib, M., Salpini, R., Svicher, V., Corona, A., Malune, P., Tramontano, E., et al. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00282 · Cited by 18
Kim, J.-M., Yoo, M., Bae, S. J., Kim, J., & Lee, H. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e211 · Cited by 18
Tsai, Y., Wu, J., Liu, T., Chuang, M., Hsu, W., Huang, P., Lai, C., Tsai, K., & Shiue, Y. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28869 · Cited by 18
Memory B cell development elicited by mRNA booster vaccinations in the elderly
Wang, Z., Muecksch, F., Raspe, R., Johannsen, F., Turroja, M., Canis, M., ElTanbouly, M. A., Santos, G. S. S., Johnson, B., Baharani, V. A., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20230668 · Cited by 19
Wu, J., Liu, M., Liu, T., Chuang, M., Hsu, W., Huang, P., Tsai, Y., & Lai, C. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106984 · Cited by 18
Piñana, J. L., Heras, I. D. L., Aiello, T. F., García‐Cadenas, I., Vázquez, L., López‐Jiménez, J., Chorão, P., Aroca, C., García‐Vidal, C., Arroyo, I., et al. (2023) · Viruses · doi:10.3390/v15102066 · Cited by 18
A community effort in SARS‐CoV‐2 drug discovery
Schimunek, J., Seidl, P., Elez, K., Hempel, T., Le, T., Noé, F., Olsson, S., Raich, L., Winter, R., Gökcan, H., et al. (2023) · Molecular Informatics · doi:10.1002/minf.202300262 · Cited by 18
Meyerowitz, E. A., & Li, Y. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad685 · Cited by 18
Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong
Cheung, Y. Y. H., Lau, E. H. Y., Yin, G., Lin, Y., Cowling, B. J., & Lam, K. F. (2023) · Emerging infectious diseases · doi:10.3201/eid3001.230414 · Cited by 18
Timbrook, T. T., Glancey, M., Noble, B. A., Eng, S., Heins, Z., Hommel, B., Tessonneau, M., Galvin, B. W., & Macalino, G. E. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03423-23 · Cited by 18
Wang, S., Sun, J., Zhang, X., Li, M., Qin, B., Liu, M., Zhang, N., Wang, S., Zhou, T., Zhang, W., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102468 · Cited by 18
New Thiazolidine-4-One Derivatives as SARS-CoV-2 Main Protease Inhibitors
Messore, A., Malune, P., Patacchini, E., Madia, V. N., Ialongo, D., Arpacioglu, M., Albano, A., Ruggieri, G., Saccoliti, F., Scipione, L., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17050650 · Cited by 18
Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer
Kotagiri, S., Blazanin, N., Xi, Y., Han, Y., Qudratullah, M., Liang, X., Wang, Y., Pandey, P., Mazhar, H., Lam, T., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.09.004 · Cited by 18
Virologic Response and Safety of Ibuzatrelvir, A Novel SARS-CoV-2 Antiviral, in Adults With COVID-19
Mortezavi, M., Sloan, A., Singh, R. S. P., Chen, L. F., Kim, J. H., Shojaee, N., Toussi, S. S., Prybylski, J. P., Baniecki, M. L., Bergman, A. J., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae529 · Cited by 18
Self-citationScaglione, V., Rotundo, S., Marascio, N., Marco, C. D., Lionello, R., Veneziano, C., Berardelli, L., Quirino, A., Olivadese, V., Serapide, F., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07774-9 · Cited by 18
Update on Immune Checkpoint Inhibitor Enterocolitis
Kelly‐Goss, M. R., Badran, Y. R., & Dougan, M. L. (2022) · Current Gastroenterology Reports · doi:10.1007/s11894-022-00852-7 · Cited by 18
Antiviral drugs against SARS-CoV-2
Aiello, T. F., García‐Vidal, C., & Soriano, À. (2022) · Revista Española de Quimioterapia · doi:10.37201/req/s03.03.2022 · Cited by 18
Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model
Johnson, D. M., Brasel, T., Massey, S., Garron, T. M., Grimes, M., Smith, J. N., Torres, M., Wallace, S. M., Tezanos, A. G. V., Beasley, D. W. C., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105492 · Cited by 18
Manciulli, T., Spinicci, M., Rossetti, B., Antonello, R. M., Lagi, F., Barbiero, A., Chechi, F., Formica, G., Francalanci, E., Alesi, M., et al. (2023) · Viruses · doi:10.3390/v15020438 · Cited by 19
Maranda, B., Labbé, S. M., Lurquin, M., Brabant, P., Fugère, A., Larrivée, J., Grbic, D. M., Leroux, A., Leduc, F., Finzi, A., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00393-6 · Cited by 19
Patel, V., Yarwood, M. J., Levick, B., Gibbons, D. C., Drysdale, M., Kerr, W. A., Watkins, J. D., Young, S., Pierce, B. F., Lloyd, E. J., et al. (2022) · medRxiv · doi:10.1101/2022.11.28.22282808 · Cited by 18
Strategy to overcome a nirmatrelvir resistance mechanism in the SARS-CoV-2 nsp5 protease
Neilsen, G., Lan, S., Slack, R. L., Lorson, Z. C., Castaner, A. E., Lee, R., Edwards, K. G., Zhang, H., Lee, J., Cantara, W. A., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv8875 · Cited by 17
Discovery of Covalent Ligands with AlphaFold3
Shamir, Y., Gabizon, R., Rogel, A., Lin, D. Y.-W., Andreotti, A. H., & London, N. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c22222 · Cited by 18
Qaseem, A., Yost, J., Miller, M. C., Andrews, R. A., Jokela, J. A., Forciea, M. A., Abraham, G. M., & Humphrey, L. L. (2022) · Annals of Internal Medicine · doi:10.7326/m22-2249 · Cited by 17
Batool, S. A., Vuthaluru, K., Hassan, A., Bseiso, O., Tehseen, Z., Pizzorno, G., Reyes, Y. R., & Saleem, F. (2023) · Cureus · doi:10.7759/cureus.33676 · Cited by 17
SARS‐CoV‐2 vaccine antibody response and breakthrough infections in transplant recipients
Vanlerberghe, B. T. K., Vrij, C., Bogaerts, K., Vermeersch, P., Lagrou, K., Molenberghs, G., Rega, F., Ceulemans, L. J., Raemdonck, D. E. V., Jochmans, I., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28736 · Cited by 17
Chou, O., Juang, Y.-P., Chao, T., Tsai, S., Chiu, P.-F., Chiou, C., Tsai, K., Chang, S., Liang, P., & Wong, C. (2023) · Journal of Natural Products · doi:10.1021/acs.jnatprod.3c00104 · Cited by 17
Paxlovid reduces the risk of Long COVID in patients six months after hospital discharge
Wang, Y., Zhao, D., Xiao, W., Shi, J., Chen, W., Jia, Q., Zhou, Y., Wang, R., Chen, X., & Feng, L. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29014 · Cited by 17
Salmanton‐García, J., Marchesi, F., Koehler, P. A., Weinbergerová, B., Čolović, N., Falces‐Romero, I., Buquicchio, C., Farina, F., Praet, J. T. V., Biernat, M., et al. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106952 · Cited by 17
Longo, B. M., Venuti, F., Gaviraghi, A., Lupia, T., Ranzani, F. A., Pepe, A., Ponzetta, L., Vita, D., Allice, T. G., Gregorc, V., et al. (2023) · Antibiotics · doi:10.3390/antibiotics12091460 · Cited by 17
From Emergence to Endemicity: A Comprehensive Review of COVID-19
Naik, R., Avula, S., Palleti, S. K., Gummadi, J., Ramachandran, R., Chandramohan, D., Dhillon, G. S., Gill, A. S., Paiwal, K., Shaik, B. F., et al. (2023) · Cureus · doi:10.7759/cureus.48046 · Cited by 17
Zhou, L., Liu, R., Pathak, H., Wang, X., Jeong, G. H., Kumari, P., Kumar, M., & Yin, J. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.3c00418 · Cited by 17
Zhu, X., Li, L., Dai, B., Liu, Z., Wang, Z., Cui, L., Gao, S., Chen, W., Tao, X., & Xu, D. (2024) · International Journal of Analytical Chemistry · doi:10.1155/2024/6139928 · Cited by 17
Jiang, J., Li, Y., Jiang, Q., Jiang, Y., Qin, H., & Li, Y. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106190 · Cited by 17
Ridgway, H. F., Moore, G. J., Gadanec, L. K., Zulli, A., Apostolopoulos, V., Hoffmann, W., Wegrzyn, K. E., Vassilaki, N., Mpekoulis, G., Zouridakis, M., et al. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2362675 · Cited by 17
Hoste, A. C. R., Smeralda, W., Cugnet, A., Brostaux, Y., Deleu, M., Garigliany, M., & Jacques, P. (2024) · Applied and Environmental Microbiology · doi:10.1128/aem.01036-24 · Cited by 17
de Reus, Y. A., Hagedoorn, P., Sturkenboom, M. G. G., Grasmeijer, F., Bolhuis, M. S., Sibum, I., Kerstjens, H. A. M., Frijlink, H. W., & Akkerman, O. W. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272034 · Cited by 17
Bartoletti, M., Azap, Ö. K., Barac, A. M., Bussini, L., Ergönül, Ö., Krause, R. G. E., Martín‐Quirós, A., Paño‐Pardo, J. R., Power, N., Sibani, M., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.08.013 · Cited by 17
Guyon, J., Novion, M., Fulda, V., Ducint, D., Molimard, M., Couzi, L., Kaminski, H., Salvo, F., & Bouchet, S. (2022) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.2c00204 · Cited by 17
Takayama, S., Yoshino, T., Koizumi, S., Irie, Y., Suzuki, T., Fujii, S., Katori, R., Kainuma, M., Kobayashi, S., Nogami, T., et al. (2022) · Internal Medicine · doi:10.2169/internalmedicine.0027-22 · Cited by 17
Sommer, I., Dobrescu, A. I., Ledinger, D., Moser, I., Thaler, K. J., Persad, E., Fangmeyer, M., Emprechtinger, R., Klerings, I., & Gartlehner, G. (2022) · Annals of Internal Medicine · doi:10.7326/m22-2202 · Cited by 17
Comparison of COVID-19 Pandemic Waves in 10 Countries in Southern Africa, 2020–2021
Smith-Sreen, J., Miller, B. M., Kabaghe, A. N., Kim, A. A., Wadonda-Kabondo, N., Frawley, A. A., Labuda, S. M., Manuel, E., Frietas, H., Mwale, A., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2813.220228 · Cited by 17
African clinical trial denied access to key COVID drug Paxlovid
Ledford, H. K., & Maxmen, A. (2022) · Nature · doi:10.1038/d41586-022-00919-5 · Cited by 17
Metadata
- Authors
- Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., Pypstra, R., & Rusnak, J. M.
- Affiliations
- Pfizer (United States) (US)
- From Global Product Development, Pfizer, Collegeville, PA (J.H., H.L.-T.); Global Product Development (A.G.) and Early Clinical Development (M.L.B.), Pfizer, Cambridge, MA; Global Product Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global Product Development, Pfizer, Tampa, FL (J.M.R.).
- Corresponding author
- Hammond, Jennifer
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-04-14
- Volume
- 386
- Issue
- 15
- Pages
- 1397-1408
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8908851
- OpenAlex
- W4212904481
- Cited by
- 2,323
- References
- 21
- Citations by year
- 2026: 186 · 2025: 319 · 2024: 517 · 2023: 769 · 2022: 525
- FWCI
- 261.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Keywords
- nirmatrelvir, COVID-19 pandemic, SARS-CoV-2, Mpro inhibitors, ritonavir, oral antiviral therapy, high-risk adults, non-hospitalized patients, viral load, unvaccinated patients, early treatment, SARS-CoV-2 variants, Omicron variant
- MeSH terms
- Viral Protease Inhibitors, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Administration, Oral, Adult, Antiviral Agents, Double-Blind Method, Drug Combinations, Hospitalization, Humans, Lactams, Leucine, Nitriles, Proline, Vaccination, Treatment Outcome, Disease Progression, Ritonavir, Viral Load
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
